Akari Therapeutics (AKTX)
NASDAQ:AKTX
Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$0.28
-$0.09(-6.73%)
At close: 4:00 PM EST
$0.28
-$0.09(-6.73%)
Day’s Range― - ―
52-Week Range$3.02 - $56.80
Previous CloseN/A
Volume16.29K
Average Volume (3M)1.63M
Market Cap
$18.81M
Enterprise Value$16.77M
Total Cash (Recent Filing)$2.77M
Total Debt (Recent Filing)$732.00K
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$27.00Price Target Upside9542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipStrategic partnership to accelerate ADC payload development can advance technical progress and increase the likelihood of reaching key program milestones.
Therapeutic DifferentiationPH1 payload is mechanistically distinct from commonly used ADC toxic payloads, offering a novel therapeutic approach that could expand potential clinical benefits if validated.
Bears Say
Analyst RatingAnalyst's downgrade to Hold cites elevated financing risk tied to the phase one ADC program, prompting a more cautious market view and limiting near-term upside.
Capital Raising And LiquidityExtremely low market capitalization and a reduced American Depositary Share public float make raising new capital more difficult and heighten dilution and liquidity risks for shareholders.
Cash PositionVery limited cash balance appears insufficient to sustain operations through key development stages, increasing pressure to obtain additional funding.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $56.80 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $18.81M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is May 20, 2027 which is in 353 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,144,588 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
AKTX Stock 12 Month Forecast
Average Price Target
$27.00
▲(9542.86% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---